Arthritis News and Research

Latest Arthritis News and Research

Scientists identify new pathway to control immune balance

St. Jude Children's Research Hospital scientists have identified a new pathway that helps control the immune balance through reciprocal regulation of specialized T lymphocytes, which play very different inflammatory roles.

21 Sep 2010

Arrayit installs microarray platform at NIH

Arrayit Corporation has completed installation and technical training of its proprietary microarray platform at the National Institute of Mental Health, National Institutes of Health, in Rockville, Maryland. In 2010, the NIH will invest more than $31.2 billion in medical research for the American people through 50,000 competitive grants to 325,000 researchers at 3,000 universities, hospitals, companies, medical schools and scientific institutions in the United States and around the world.

21 Sep 2010

Pollution increases risk for sudden cardiac arrest

The fine particles of pollution that hang in the air can increase the risk for sudden cardiac arrest, according to a new study conducted by a team from Long Island Jewish (LIJ) Medical Center and The Feinstein Institute for Medical Research.

21 Sep 2010

Public health at risk as Vitamin D evidence mounts

A group of prevention-focused healthcare organizations has expressed deep concern over recently-proposed restrictions to OHIP coverage of Vitamin D testing in the province. The proposed new legislation will delist OHIP insured Vitamin D testing for most Ontarians. Exceptions will be made for those with osteoporosis, malabsorption syndromes, and individuals taking medications that interfere with vitamin D absorption or metabolism.

21 Sep 2010

NIAMS awards $684,000 SBIR grant to Signum Biosciences to develop GPCR modulating therapeutics

Signum Biosciences, Inc. was recently awarded two Small Business Innovation Research (SBIR) Phase I grants by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the NIH, totaling over $684,000 for development of novel G-protein coupled receptor (GPCR) modulating therapeutics designed to treat common skin disorders.

20 Sep 2010

URB937 drug boosts natural painkiller level: Study

A new study has shown how a novel compound boosts levels of a natural painkiller at the site of an injury. The ground-breaking study published today in Nature Neuroscience shows how the potential drug URB937 acts in peripheral tissue and may have the potential to relieve pain without the side effects associated with many current painkillers that act centrally on the nervous system.

20 Sep 2010

Murphy Analytics releases report on Bohai Pharmaceuticals

Bohai Pharmaceuticals Group, Inc., a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today announced the release of an in-depth initiation report by Patrick Murphy, CFA, principal of fee-based independent research firm Murphy Analytics.

18 Sep 2010

Ligand Pharmaceuticals transfers license rights to Proximagen for CXCR4 target

Ligand Pharmaceuticals Incorporated announced today that it has transferred exclusive license rights to Proximagen Limited for a series of compound hits related to the CXCR4 target with application for a number of indications including those related to the central nervous system. Ligand will receive an upfront payment and continue to be entitled to receive potential future milestone and royalty payments.

18 Sep 2010

Conference to discuss frontline of immunological research, its clinical application

The immune system is evolved to protect our body against a variety of infectious agents which can cause serious and often fatal diseases. We now appreciate that the immune system is also involved in surveillance of malignant transformation of normal cells that constitute our body, as well as rejection of transplanted organs.

17 Sep 2010

SBi reports continuing growth for S.T.A.R. ankle arthroplasty implant system

Small Bone Innovations, Inc. (SBi), a leading, privately held orthopedics company focused primarily on arthroplasty and trauma reconstruction technology and treatments for the small bones & joints, reported continuing growth for its S.T.A.R. ankle arthroplasty implant system with August being the biggest month ever for the S.T.A.R. in terms of revenues and surgeries.

From Evident Corporation - Life Sciences 17 Sep 2010

Prometheus, Tarrot announce exclusive agreement for Crohn's Disease treatment

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and Tarrot Laboratories, a business unit of Cedars-Sinai Medical Center, today announced the execution of an exclusive research collaboration and license agreement. The collaboration will focus on identifying genetic or serologic markers associated with clinical responses to anti-TNF therapies such as Cimzia, Humira and Remicade utilized in the treatment of Crohn's Disease, and the subsequent development of diagnostic tests.

17 Sep 2010

Study identifies venous thromboembolism risk factors after THR surgery

Risk factors for venous thromboembolism after total hip replacement (THR) surgery were identified in a new study published in the September 2010 issue of The Journal of Bone and Joint Surgery (JBJS). While the rate of thromboembolism has been significantly reduced through medication, understanding the risk factors could further reduce the likelihood of patients developing this potentially fatal complication.

17 Sep 2010

Scientists discover new drug target to improve radiation effectiveness for treating cancer

Scientists at Washington University School of Medicine in St. Louis have discovered a new drug target that could improve the effectiveness of radiation for hard-to-treat cancers.

17 Sep 2010

ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease

ISTA Pharmaceuticals, Inc., today announced that it has initiated a Phase 3 clinical program of ISTA's proprietary formulation of REMURA (bromfenac ophthalmic solution for dry eye) for alleviating the signs and symptoms of dry eye disease. The Phase 3 efficacy studies are being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).

16 Sep 2010

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

BioCryst Pharmaceuticals, Inc. announced positive top-line results from its randomized, double-blind, multi-center, placebo-controlled Phase 2 study designed to evaluate the urate-lowering activity and safety of several doses of BCX4208 alone and in combination with selected doses of allopurinol administered once-daily.

16 Sep 2010

Endoscopic laser spine procedures replace traditional open back surgery

The Bonati Spine Institute, the leading center for the patented Bonati Spine Procedures for minimally invasive laser spine surgery, supports recent studies by highly respected organizations such as the Journal of the America Board of Family Medicine and Consumer Reports reporting an unnecessary growth in tests and treatments targeting back pain.

16 Sep 2010

Researchers to conduct gene analysis for ankylosing spondylitis

A new study designed to test suspected links between genes and two immune disorders could open the door to better ways to diagnose and treat the conditions that affect a combined total of approximately 2.5 million people in the United States, report scientists at The University of Texas Health Science Center at Houston (UTHealth).

16 Sep 2010

GSK, Genmab to refocus on ofatumumab development program in autoimmune indications

GlaxoSmithKline and Genmab A/S Following the 1st July announcement by GSK and Genmab of an amendment to the collaborative agreement for ofatumumab in which GSK assumed development responsibility for autoimmune indications, GSK and Genmab announced today plans to refocus the development program of ofatumumab in autoimmune indications.

16 Sep 2010

HHS awards grant to develop patient-centered outcomes research

U.S. Department of Health and Human Services (HHS) Assistant Secretary for Health, Howard K. Koh, MD, MPH, today announced the award of more than $14 million to develop, implement, and test strategies to increase the adoption and dissemination of interventions based on patient-centered outcomes research among racial and ethnic minority populations.

16 Sep 2010

Bohai adds additional pharmaceutical products to Traditional Chinese Medicine portfolio

Bohai Pharmaceuticals Group, Inc., a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today announced the introduction of five additional pharmaceutical products to its portfolio of TCM offerings.

15 Sep 2010

Arthritis News and Research

Latest Arthritis News and Research

Scientists identify new pathway to control immune balance

Arrayit installs microarray platform at NIH

Pollution increases risk for sudden cardiac arrest

Public health at risk as Vitamin D evidence mounts

NIAMS awards $684,000 SBIR grant to Signum Biosciences to develop GPCR modulating therapeutics

URB937 drug boosts natural painkiller level: Study

Murphy Analytics releases report on Bohai Pharmaceuticals

Ligand Pharmaceuticals transfers license rights to Proximagen for CXCR4 target

Conference to discuss frontline of immunological research, its clinical application

SBi reports continuing growth for S.T.A.R. ankle arthroplasty implant system

Prometheus, Tarrot announce exclusive agreement for Crohn's Disease treatment

Study identifies venous thromboembolism risk factors after THR surgery

Scientists discover new drug target to improve radiation effectiveness for treating cancer

ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

Endoscopic laser spine procedures replace traditional open back surgery

Researchers to conduct gene analysis for ankylosing spondylitis

GSK, Genmab to refocus on ofatumumab development program in autoimmune indications

HHS awards grant to develop patient-centered outcomes research

Bohai adds additional pharmaceutical products to Traditional Chinese Medicine portfolio

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Arthritis News and Research

Latest Arthritis News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in